Longitudinal Clinical Intelligence · B2B HealthTech · Systemic Lupus Erythematosus

From fragmented records
to a longitudinal view
of lupus.

Proprietary clinical intelligence software, designed with purpose.

Demonstration environment with synthetic data — not for clinical use. Full regulatory notice →

Request an MVP Demo Explore Institutional Evaluation →
Patient SYN-0042 · SLE · follow-up 2023–2026 Synthetic data — illustrative
  • Dec 2023Clinical visit
  • Jun 2024Treatment update
  • Feb 2025Lab result logged
Every point traces back to its source record — full provenance, no black box.
SLEDAI-2K · activity trajectory — in development, not yet calculated —
Recorded visit Planned visit

Conceptual visualisation — does not correspond to a functional MVP interface.

5M+
Over 5 million people worldwide live with lupus
AI-First
Clinical architecture with native intelligence
MDR
Regulatory-aligned design
EU
Regulatory-aware design
About SLECAI

A technology company
born from the clinic.

SLECAI Health Intelligence, S.L. es una empresa tecnológica española especializada en el desarrollo de software clínico e inteligencia artificial para enfermedades autoinmunes sistémicas, con foco inicial en el Lupus Eritematoso Sistémico (LES).

Fundada por el Dr. Juan Carlos García Moraga, especialista en Medicina Interna y Enfermedades Autoinmunes Sistémicas con experiencia clínica directa, SLECAI traduce conocimiento científico validado en herramientas digitales de estructuración clínica: referencias de actividad de enfermedad, indicadores de seguridad, organización longitudinal de datos clínicos y soporte para revisión clínica estructurada.

La empresa se encuentra en fase de desarrollo activo, con foco en arquitectura de software, protección de activos de propiedad intelectual, bases regulatorias y desarrollo de alianzas estratégicas. Cualquier actividad comercial o regulada vinculada a la solución se iniciará únicamente tras obtener las autorizaciones, licencias y habilitaciones correspondientes. En esta fase, la plataforma opera en entorno demostrativo con datos sintéticos, sin captación ni procesamiento de datos clínicos reales.

A SLECAI Health Intelligence company

🧬
Science-led product
Every product decision stems from internationally validated clinical evidence. SLEDAI-2K, BILAG-2004, LLDAS and DORIS 2021 are foundational, not optional.
🤖
Responsible AI
Artificial intelligence applied to healthcare with a regulatory-first approach: privacy by design, alignment with the EU AI Act and transparent model documentation.
🔐
Protected intellectual property
Proprietary software, clinical-technical know-how managed as a confidential asset, and SLECAI® trademark registered with the OEPM (filing M4380703).
🇪🇺
European-scale ambition
Designed for licensing, international expansion and R&D contracts with hospitals, insurers and academic centres across the European healthcare landscape.

Nota legal importante: SLECAI Health Intelligence, S.L. se encuentra en fase de desarrollo activo. La empresa no presta consulta médica, diagnóstico, tratamiento ni servicios sanitarios regulados. Cualquier actividad regulada se iniciará únicamente tras obtener todas las autorizaciones, licencias y habilitaciones correspondientes.

Health Intelligence

Proprietary software. Clinical intelligence.
Purpose-built design.

B2B HealthTech · Proprietary Software · Barcelona · 2026

Demonstration environment with synthetic data · No diagnostic or therapeutic intent at this stage · Regulatory preparation in progress

Platform Vision

What we are
building.

A modular clinical intelligence ecosystem covering the full care cycle for patients with systemic autoimmune disease. Currently in development — no clinical data is collected or processed at this stage.

01
📊
Clinical Scoring Engine
Automated calculation of validated indices: SLEDAI-2K, BILAG-2004, LLDAS, DORIS 2021 and SDI. Longitudinal tracking of disease activity and cumulative organ damage.
Core Module
02
🚨
Pharmacological Safety Alerts
Pharmacological safety alert framework covering toxicity thresholds, cumulative dose limits and contraindications — currently in development with synthetic data, not intended for clinical use or therapeutic decision-making.
Safety AI
03
🔬
Biomedical Data Analytics
Exploration and visualisation of laboratory, serology and biopsy data. Pattern analysis designed to support longitudinal research follow-up — currently in development with synthetic data, not intended for diagnostic or direct clinical use.
Analytics
04
📋
Structured Clinical Management
Autoimmune-specific structured patient history. Visit records, treatment tracking, comorbidities, pregnancy, vaccination status and multidisciplinary follow-up.
EMR Module
05
🧪
Research Data Module
Structured data export for observational studies, clinical trials and publications. Designed for HL7/FHIR interoperability with hospital information systems.
Research
06
🌐
API & Licensing Architecture
Integration-ready for hospital HIS, telemedicine platforms and insurer systems. B2B licensing model and clinical SaaS for multi-centre deployment.
Integration

Technology stack & compliance framework

SLECAI is designed from the ground up with regulatory compliance, clinical interoperability and data security as primary constraints — not afterthoughts.

SLEDAI-2KBILAG-2004LLDASDORIS 2021HL7 / FHIREU AI ActMDR AlignedGDPR by DesignReal World DataMLOps ClinicalCNAE 6210 · 7210ISO 27001 target
Request Briefing →
Clinical use cases

Lupus and systemic autoimmune diseases.

SLECAI starts with systemic lupus erythematosus as its first clinical use case.

Foundational use case

Systemic Lupus Erythematosus

SLECAI supports longitudinal organisation of SLE clinical information, validated activity indices, treatment safety review and structured follow-up, always under professional supervision.

Central use case
Planned expansion

Expansion to other diseases

Future expansion to other systemic autoimmune diseases is subject to clinical and regulatory validation.

Features are in development with synthetic data and are not clinically validated at this stage.

View platform
Founder
Dr. Juan Carlos García Moraga — Especialista en Medicina Interna y Enfermedades Autoinmunes Sistémicas, Fundador de SLECAI Health Intelligence
Dr. Juan Carlos García Moraga
Founder & Chief Executive

Dr. Juan Carlos
García Moraga

Specialist in Internal Medicine & Systemic Autoimmune Diseases · Founder & Administrator · SLECAI Health Intelligence, S.L.

Dr. García Moraga is a specialist in Internal Medicine and Systemic Autoimmune Diseases with direct clinical experience in the management of complex autoimmune conditions including Systemic Lupus Erythematosus, myositis, systemic vasculitis and connective tissue diseases.

SLECAI emerged from the intersection of frontline clinical knowledge and the conviction that artificial intelligence, applied responsibly and with scientific rigour, can meaningfully transform how autoimmune conditions are monitored, scored and managed over time. The platform's architecture — from scoring logic to alert design — is rooted in direct clinical expertise.

Specialist in Internal Medicine and Systemic Autoimmune Diseases
Clinical expertise in SLE, myositis, systemic vasculitis and connective tissue disease
Founder & Sole Administrator, SLECAI Health Intelligence, S.L.
Trademark holder: SLECAI — OEPM Classes 9, 35, 42 & 44
Based in Igualada, Catalunya, Spain — serving a European market
"The complexity of autoimmune disease demands intelligence that is both clinical and computational. SLECAI is built on the belief that the best medical software is designed by those who have spent years at the bedside."
— Dr. Juan Carlos García Moraga, Founder
For healthcare institutions

Built for clinical teams.

SLECAI supports institutional review of complex autoimmune care, without replacing medical judgement.

Longitudinal overview

Structured clinical timelines to support review, coordination and follow-up.

Structured clinical data

Organised clinical, laboratory and follow-up parameters to reduce fragmentation in complex diseases.

Longitudinal follow-up

Support for disease-course review aligned with treat-to-target models.

Therapeutic safety

Reference framework for toxicity monitoring and drug interactions in long-term treatments, under clinical supervision.

Committee preparation

Structured information organised for multidisciplinary committees and complex case reviews.

Clinical traceability

Structured follow-up records compatible with healthcare quality standards.

Request institutional meeting

Professional and institutional enquiries only

Marco Regulatorio

Desarrollo alineado con
las directrices de
iSalut · IA en Salud

SLECAI Health Intelligence desarrolla su plataforma siguiendo las directrices del Programa de Inteligencia Artificial en Salud de la Generalitat de Catalunya, impulsado por el Departament de Salut a través de iSalut.

Este marco asegura que los sistemas de IA aplicados a la salud se desarrollen con rigor clínico, transparencia algorítmica, protección de datos, equidad y sostenibilidad. SLECAI integra estas directrices como eje estructural de su arquitectura tecnológica y de su estrategia regulatoria ante el MDR y el AI Act europeo.

🔬
Rigor clínico
Algoritmos validados clínicamente antes de su implantación. Sin decisiones automáticas no supervisadas por el clínico.
🔍
Transparencia algorítmica
Modelos explicables (XAI). El clínico siempre puede auditar el razonamiento del sistema y mantiene la autoridad de decisión.
⚖️
Equidad y no discriminación
Evaluación de sesgos en los datos de entrenamiento. Diseño inclusivo para evitar desigualdades en la atención a pacientes autoinmunes.
🛡️
Gobernanza y supervisión
Sistema de gobernanza de IA alineado con el marco catalán e implantado conforme al Reglamento (UE) 2024/1689 (AI Act) para sistemas de alto riesgo en salud.
Programa iSalut · IA en Salud
iasalut.cat/es/programa-salut-ia  ↗
Departament de Salut · Generalitat de Catalunya — marco de referencia para el desarrollo responsable de IA en el sistema de salud catalán.
iSalut · IA en Salud
Generalitat de Catalunya
✓ Desarrollo con rigor clínico validado
◑ Transparencia algorítmica (XAI)
✓ Protección de datos RGPD/GDPR
◑ Equidad y no discriminación
◑ Supervisión clínica humana obligatoria
◑ AI Act (UE) 2024/1689 — en proceso
◑ MDR (UE) 2017/745 — en proceso
Arquitectura AI-aware en entorno demostrativo con datos sintéticos, orientada a estructuración longitudinal de información clínica y desarrollo regulatoriamente prudente.
🇪🇺 EU AI Act 2024/1689 🏥 MDR 2017/745 ✅ GDPR · RGPD 🏴 iSalut Catalunya 📋 OWASP Healthcare 🔒 ISO 27001 (target) ⚙️ ENS (target)
Institutional presence

Ecosystem presence

SLECAI Health Intelligence is progressively integrating into the Catalan health innovation ecosystem and is listed in relevant life sciences, startup and investment platforms.

Biocat
Catalonia Health and Life Sciences Data Platform

Listed in Biocat's Catalonia Health and Life Sciences Data Platform.

Biocat View official registry
ACCIÓ
Barcelona & Catalonia Startup Hub

Listed in the Barcelona & Catalonia Startup Hub.

ACCIÓ View official registry
Biocat
Health Innovation Catalonia

Registered in Biocat's health innovation and investment ecosystem.

Biocat View official registry
ENISA
ENISA-Certified Startup

SLECAI Health Intelligence, S.L. is certified as an innovative, scalable startup by ENISA (14/10/2026), recorded in the official Spanish business registry bulletin BORME-A-2026-209-08 (29/10/2026). The certification refers to the company's business status, not to clinical or regulatory validation of the software.

ENISA View official registry

Listing in these platforms reflects presence in public innovation and ecosystem registries. It does not imply clinical validation, secured funding, formal partnership or institutional endorsement.

Research and innovation

Clinical AI under professional supervision.

SLECAI develops clinical intelligence tools with scientific methodology, human oversight and progressive validation.

Synthetic cohorts

Methodology validated with clinically coherent synthetic data, without using real patient data.

Progressive clinical validation

Staged external evaluation oriented to institutional pilots and real-world evidence generation.

Evidence-based medicine

Internationally validated indices as foundation: SLEDAI-2K, BILAG-2004, LLDAS and DORIS 2021.

Regulatory-aware architecture

Traceability, security and human oversight aligned with EU AI Act, MDR and GDPR.

"Every product decision starts from internationally validated clinical evidence — activity and damage indices are not optional, they are the starting point."
1 SLEDAI-2K — Gladman DD, Ibañez D, Urowitz MB. J Rheumatol. 2002;29(2):288–291.
2 BILAG-2004 — Isenberg DA, et al. Rheumatology (Oxford). 2005;44(7):902–906.
3 LLDAS — Franklyn K, et al. Ann Rheum Dis. 2016;75:1615–1621.
4 DORIS 2021 — van Vollenhoven RF, et al. Lupus Sci Med. 2021;8:e000538.

All four are published clinical instruments validated in the scientific literature — not SLECAI's own validation results. Their automated calculation is in technical development and no independent validation of the implementation has been completed yet.

Explore research collaboration
Partnerships & Sponsorship

Build the future of
autoimmune care
with us.

We are actively seeking sponsors, strategic partners and aligned investors who share our vision: making autoimmune medicine a specialty with world-class clinical intelligence.

Hospitals & Clinical Centres
Funded clinical pilots, co-investigation, algorithm validation, anonymous data research and joint publications.
Pharmaceutical Industry
Collaboration on real-world evidence studies, patient registry support, clinical trial integration and R&D contracts in internal medicine and rare diseases.
Foundations & Grants
Non-dilutive funding via European grants (Horizon, EIC), national funding (CDTI, Torres Quevedo) and private biomedical research foundations.
Insurers & Mutuals
Licensing of chronic patient management modules, reduction of hospitalisation costs and optimisation of autoimmune follow-up protocols at scale.
Universities & Academia
Technology transfer agreements, innovation chairs, co-publication and access for research groups in internal medicine, immunology and clinical data science.
Strategic Investors
Impact investment in digital health. We prioritise investors experienced in European medtech with a long-term horizon.
Start a conversation →

We respond within 48 hours · NDA available before any technical briefing

Cybersecurity

Security &
Trust Infrastructure.

SLECAI is engineered with security from the first commit. Clinical data protection and partner trust are architectural constraints, not optional features.

🔒
Privacy by Design
GDPR-by-Design architecture: data minimisation, pseudonymisation, defined retention periods and data subject rights implemented in the system core.
🛡️
Encryption in Transit and at Rest
All data in transit encrypted with TLS 1.3+. Data at rest encrypted with AES-256. Key management with automatic rotation and least-privilege access.
🪪
Access Control and Identity Management
Multi-factor authentication (MFA) and role-based access control (RBAC) by clinical role — in design and progressive implementation. Short-expiry sessions and a full audit trail of access and actions are planned as part of the architecture.
📋
Compliance Framework
Alignment with ISO/IEC 27001, ENS (Esquema Nacional de Seguridad), OWASP Top 10 and EU AI Act cybersecurity requirements for high-risk AI systems.
⚙️
Code Security and DevSecOps
Code review, static analysis (SAST) and software composition analysis (SCA) planned as part of the development process. Dependency management with automated CVE vulnerability alerts — in implementation.
🚨
Incident Response Plan
Response and notification procedure per GDPR Article 33 — in design. BCP and DRP planned. Periodic external security audits planned.
Current security posture
Website secured
Privacy by design
No patient data collected. Architecture designed for GDPR compliance from inception.
Regulatory-aware architecture
System design aligned with EU AI Act requirements and MDR classification pathways.
Secure infrastructure
HTTPS enforced, security headers applied, no third-party tracking. Regular dependency review.
Audit-ready documentation
Privacy policy, cookie policy, and data processing documentation maintained and versioned.
✓
No patient data collected at this stage
✓
HTTPS site with security headers applied
✓
Documented privacy and cookie policy
✓
No third-party tracking cookies
✓
Contact form with no sensitive data storage
✓
Regular dependency and vulnerability review
"Security and privacy architecture is designed with the applicable regulatory frameworks as the starting point, not as something added afterwards."
1 GDPR Article 33 — breach notification
2 Regulation (EU) 2024/1689 — AI Act
3 ISO/IEC 27001 — information security
4 ENS — Spanish National Security Framework
🔒 TLS 1.3+ 🛡️ AES-256 ✅ GDPR by Design 🤖 EU AI Act Aligned ⚙️ ISO 27001 (target) 📋 OWASP Top 10 ✅ No Tracking Cookies 🔐 MFA (in progress) 🔍 SAST / SCA (in progress) 📑 ENS (target)
Responsible Disclosure Notice
SLECAI supports ethical security research. If you discover a vulnerability, contact us confidentially through our official form before any public disclosure.
Contact the security team →
Contact

Let's talk.

Whether you are a potential sponsor, clinical collaborator, researcher, investor or prospective team member — we want to hear from you.

Location
Igualada, Catalunya, Spain
Website
www.slecail.com
Legal entity
SLECAI Health Intelligence, S.L. · CNAE 6210 · España
Status
B2B HealthTech activa — desarrollo de software propietario y colaboración estratégica

Please do not include patient-identifiable or sensitive clinical data in this form.

By submitting this form you consent to SLECAI Health Intelligence, S.L. contacting you. No medical advice is provided. This channel is for business and partnership enquiries only.

Your data will be processed by SLECAI Health Intelligence, S.L. to handle your business enquiry, with Formspree, Inc. (US) as the processor handling submission. It is not used for marketing without your express consent.

Read the full privacy policy →
Privacy

Contact form privacy policy

Data controller

SLECAI Health Intelligence, S.L., registered in Igualada, Catalunya, Spain (CNAE 6210), is the data controller for the personal data you provide through this website's contact form.

Purposes of processing

To manage and respond to your business enquiry: MVP demo request, institutional evaluation, research collaboration, sponsorship, strategic investment, hospital pilot programmes, public funding, joining the team, press, or other business matters.

Applicable legal bases

Where your enquiry concerns a potential business, collaboration or investment relationship, the legal basis is the performance of pre-contractual steps taken at your request (Article 6(1)(b) GDPR). For general unsolicited enquiries, the basis is SLECAI's legitimate interest in responding to business communications (Article 6(1)(f) GDPR). Consent is not the basis for this processing unless expressly requested for a separate purpose — for example, sending promotional communications, which this form does not currently collect.

Recipients and processors

The technical submission of the form is handled by Formspree, Inc., acting as data processor. SLECAI does not share this data with any additional third party, except where legally required.

International transfers

Using Formspree involves a transfer of data to the United States. Formspree's own privacy policy states that it takes steps to ensure appropriate protection, without publicly specifying the exact mechanism (such as Standard Contractual Clauses). This point is pending direct documentary verification with Formspree before this policy is finalised for publication.

Retention period

Data will be kept for as long as necessary to manage your enquiry, and for a maximum of 24 months from the last contact, unless a longer period is legally required.

Your rights

You may exercise your rights of access, rectification, erasure, objection, restriction and portability under the GDPR and Spanish Organic Law 3/2018 (LOPDGDD). You also have the right to lodge a complaint with the Spanish Data Protection Agency (AEPD, www.aepd.es).

Contact to exercise your rights

You can exercise your rights by writing to direccion@slecail.com, stating which right you wish to exercise.

Last updated: November 2026 (draft pending legal review) · SLECAI Health Intelligence, S.L.